Chun Wai Mai | Cancer | Best Researcher Award

Posted on by sciencefather

Prof. Dr. Chun Wai Mai | Cancer | Best Researcher Award

Professor, IMU University, Malaysia 🌟

Dr. Chun-Wai Mai, a highly accomplished researcher and professor from Malaysia, is devoted to understanding the mechanisms behind tumorigenesis and metastasis. With a vision to uncover the origins of cancer, Dr. Mai aims to enhance clinical prognosis and improve patient outcomes. Over the years, he has held pivotal academic and research roles, contributing significantly to oncology, stem cell biology, genomics, and drug discovery. His work embodies a commitment to advancing medical science and tackling cancer at its roots.

Profile

Orcid

Education 🎓

Dr. Chun-Wai Mai earned his PhD in Pharmaceutical Sciences (2010–2014) and Bachelor of Pharmacy degree (2005–2009) from the International Medical University (IMU) in Kuala Lumpur, Malaysia. His strong academic foundation has fueled his impactful contributions to cancer research and drug development.

Experience 🧑‍🔬

Dr. Mai is currently a Professor at the Centre for Cancer and Stem Cell Research, International Medical University. He previously served as an Associate Professor at UCSI University (2022–2025), a Postdoctoral Fellow at Shanghai Jiao Tong University School of Medicine (2020–2022), and as a Senior Lecturer (2018–2020) and Lecturer (2010–2018) at IMU. His extensive academic journey reflects his dedication to education and research excellence.

Research Interests 🔬

Dr. Mai’s research focuses on tumorigenesis, metastasis, stem cells, and drug discovery, with a keen interest in genomics and anticancer mechanisms. He is driven by the goal of developing targeted therapies to combat cancer and improve patient outcomes, particularly in addressing the challenges of drug resistance and cancer progression.

Awards 🏆

Dr. Mai is a distinguished member of esteemed organizations, including the European Association for Cancer Research and the Royal Society of Chemistry. His groundbreaking research has earned recognition in oncology and stem cell therapy, marking him as a leader in his field.

Publications 📚

Phytochemical Analysis and Biological Activities of Flavonoids and Anthraquinones from Cassia alata (Linnaeus) Roxburgh (Plants, 2025): 10.3390/plants14030362

Scoping Review of Enablers and Challenges of Implementing Pharmacogenomics Testing in Primary Care Settings (BMJ Open, 2024): 10.1136/bmjopen-2024-087064

Recent Developments in Luteolin-Loaded Nanoformulations for Enhanced Anti-Carcinogenic Activities (Sci, 2024): 10.3390/sci6040068

Revolutionizing Treatment for Nasopharyngeal Cancer with Stem Cell and Genetically Engineered Therapies (Frontiers in Immunology, 2024): 10.3389/fimmu.2024.1484535

Molecular Mechanism of Tocotrienol-Mediated Anticancer Properties: Systematic Review (Nutrients, 2023): 10.3390/nu15081854

Conclusion

Dr. Chun-Wai Mai’s outstanding academic background, impactful research contributions, and leadership in oncology and drug discovery make him an excellent candidate for the Best Researcher Award. His focus on advancing cancer therapies aligns with the award’s vision of recognizing transformative scientific contributions. By further showcasing patents, grants, and global collaborations, Dr. Mai’s profile could achieve even greater prominence in the scientific community.

Mohamed Eltokhy | Cancer Biology | Best Researcher Award

Posted on by sciencefather

Mr. Mohamed Eltokhy | Cancer Biology | Best Researcher Award

MSc, TTUHSC, United States

Mohamed Ashraf Eltokhy is a dedicated researcher and Assistant Lecturer at Texas Tech University Health Science Center (TTUHSC) in Abilene, Texas, where he’s contributing to the development of innovative cancer therapies. With an academic background in pharmaceutical sciences, he has experience in both clinical and academic settings, focusing on immunotherapeutic and biotechnological approaches to cancer treatment. Passionate about improving cancer therapies, he leads impactful research initiatives, aiming to advance safer, more effective treatment options for patients.

Profile

Orcid

Google Scholar

Education 🎓

Mohamed holds a Bachelor’s degree in Pharmaceutical Science from Misr International University in Cairo, graduating with high honors (GPA 3.95). He further pursued a Master of Science in Microbiology and Immunology at Al-Azhar University. Currently, he’s a PhD candidate at TTUHSC, studying in the Department of Immunotherapeutic and Biotechnology. His academic journey is marked by consistent excellence and a strong commitment to cancer research, achieving a cGPA of 3.948.

Experience 🧑‍🏫

Mohamed’s diverse experience spans research, academia, and leadership. As the CEO of Neopurpose Therapeutics, he drives strategic decisions, investor relations, and competitor analysis. In academia, he has held positions such as Assistant Lecturer at Misr International University, where he taught microbiology, immunology, and biochemistry. His research experience includes a guest researcher role at Leiden University and involvement in innovative cancer drug studies at TTUHSC, demonstrating his commitment to advancing scientific knowledge and application in cancer therapeutics.

Research Interest 🔬

Mohamed’s research focuses on developing novel anti-cancer agents and bioprinted tumor-on-chip models for drug discovery. His work includes in vitro screening of new compounds, mechanistic studies, and safety evaluations, as well as in vivo research to establish efficacy and safety. His overarching goal is to create more personalized cancer treatment options and to understand the molecular mechanisms involved in cancer progression and treatment.

Awards & Recognition 🏆

Throughout his career, Mohamed has received multiple awards, including the Texas Tech Accelerator Program Award in 2024, and a prestigious poster presentation at the American Association of Cancer Research (AACR). His excellence in academia was recognized with awards for valuable contributions at MIU’s senior conferences and honors for outstanding academic performance in Microbiology and Immunology.

Publications Top Notes 📑

  1. Dec 2021: Eltokhy, M. A., Saad, B. T., Eltayeb, W. N., Yahia, I. S., Aboshanab, K. M., & Ashour, M. S. E. “Exploring the Nature of the Antimicrobial Metabolites Produced by Paenibacillus ehimensis Soil Isolate MZ921932 Using a Metagenomic Nanopore Sequencing Coupled with LC-Mass Analysis,” Journal of Antibiotics (MDPI)..
  2. Nov 2021: Eltokhy, M. A., Saad, B. T., Eltayeb, W. N., El-Ansary, M. R., Aboshanab, K. M., & Ashour, M. S. E. “A metagenomic nanopore sequence analysis combined with conventional screening and spectroscopic methods for deciphering the antimicrobial metabolites produced by Alcaligenes faecalis soil isolate MZ921504,” Journal of Antibiotics (MDPI)..
  3. Sep 2020: Eassa, H. A., Eltokhy, M. A., Fayyaz, H. A., Khalifa, M. K. A., Shawky, S., Helal, N. A., & Nounou, M. I. “Current Topical Strategies for Skin-Aging and Inflammaging Treatment: Science versus Fiction,” Europe PMC..
  4. May 2019: Helal, N. A., Elnoweam, O., Eassa, H. A., Amer, A. M., Eltokhy, M. A., Helal, M. A., Fayyaz, H. A., & Nounou, M. I. “Integrated Continuous Manufacturing in Pharmaceutical Industry: Current Evolutionary Steps Towards Revolutionary Future,” Pharmaceutical Patent Analyst (Clarivate Analytics)..
  5. Jan 2019: Helal, N. A., Eassa, H. A., Amer, A. M., Eltokhy, M. A., Edafiogho, I., & Nounou, M. I. “Nutraceuticals’ novel formulations: the good, the bad, the unknown and patents involved,” Recent Patents on Drug Delivery & Formulation (Bentham Science)..